RPS6KA1 and acute myeloid leukemia: In conclusion, alternate TSS usage and therewith linked increased expression of RPS6KA1 compensated for the loss of RUNX1/RUNX1T1 strongly suggesting RPS6KA1 as a pharmacologic target for t(8;21) AML.